WASHINGTON — The most widely used covid-19 vaccines may offer a surprise benefit for some cancer patients — revving up their immune systems to help fight tumors.
(MedPage Today) -- BERLIN -- A single infusion of the investigational PRAME-directed T-cell receptor T-cell therapy anzutresgene autoleucel (anzu-cel) showed encouraging antitumor activity in patients with previously treated advanced or…
A new study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center has found that women with early-stage cervical cancer who received radiation plus chemotherapy reported a greater short-term decline in quality of…
Researchers have identified factors associated with survival for patients initially diagnosed with metastatic breast cancer who were seen at UT Southwestern Medical Center and its affiliated sites. Their findings, published in…
The number of people receiving treatment for cancer has risen dramatically in the last decade in many African countries. For example, 10 years ago in Ethiopia and Kenya, cancer care was available to only a few thousand patients per year in…
Elironrasib led to meaningful and durable responses in patients with metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC), including after prior treatment with KRAS G12C inhibitors and in the presence of features linked to KRAS…
Zenocutuzumab (Bizengri), a bispecific antibody that targets human epidermal growth factor receptor 2 (HER2) and HER3, led to responses in more than a third of patients with neuregulin 1 (NRG1)-positive cholangiocarcinoma, according to…
Zocilurtatug pelitecan (zoci), also known as ZL-1310, an investigational antibody-drug conjugate (ADC) that targets the protein DLL3, demonstrated both safety and capacity to induce anticancer responses in patients with extensive-stage…
(MedPage Today) -- BERLIN -- An investigational oral drug currently under review with the FDA showed durable antitumor activity in patients with HER2-mutant advanced non-small cell lung cancer (NSCLC), findings from an international phase…
FX-909, a first-in-class investigational oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma (PPARG), showed early signs of clinical benefit in patients with advanced urothelial carcinoma, according to results…
ROCKVILLE, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (I-Mab or the Company), is a global biotechnology platform company committed to accelerating access to innovative medicines for patients worldwide, today announced that…
By LAURAN NEERGAARD AP Medical Writer WASHINGTON (AP) — The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients – revving up their immune systems to help fight tumors. People with advanced lung or skin…